NYSEAMERICAN:CRMD - CorMedix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.60 -0.07 (-4.19 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$1.67
Today's Range$1.43 - $1.70
52-Week Range$0.17 - $2.40
Volume3.07 million shs
Average Volume2.78 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CRMD
Previous SymbolNYSEMKT:CRMD
CUSIPN/A
Phone+1-908-5179500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees14
Outstanding Shares105,310,000
Market Cap$0.00
OptionableOptionable

CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) released its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.10 million. View CorMedix's Earnings History.

When is CorMedix's next earnings date?

CorMedix is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for CorMedix.

What price target have analysts set for CRMD?

2 Wall Street analysts have issued 12 month price targets for CorMedix's stock. Their predictions range from $3.00 to $6.00. On average, they anticipate CorMedix's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 181.3% from the stock's current price. View Analyst Price Targets for CorMedix.

What is the consensus analysts' recommendation for CorMedix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.

Has CorMedix been receiving favorable news coverage?

News articles about CRMD stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CorMedix earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.

Are investors shorting CorMedix?

CorMedix saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 13,318,889 shares, an increase of 7.8% from the November 15th total of 12,351,937 shares. Based on an average trading volume of 2,536,101 shares, the short-interest ratio is presently 5.3 days. Approximately 13.3% of the company's stock are sold short. View CorMedix's Current Options Chain.

Who are some of CorMedix's key competitors?

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:
  • Mr. Khoso Baluch, CEO & Director (Age 60)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 62)
  • Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 39)
  • Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance

Who are CorMedix's major shareholders?

CorMedix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.54%), EAM Investors LLC (0.72%), Virtu Financial LLC (0.39%) and Franklin Resources Inc. (0.17%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix.

Which major investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc.. View Insider Buying and Selling for CorMedix.

Which major investors are buying CorMedix stock?

CRMD stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EAM Investors LLC and Virtu Financial LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $1.60.

What is CorMedix's official website?

The official website for CorMedix is http://www.cormedix.com.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.


MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel